NPI 1730756461: Open Payments
NPI 1730756461. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,010 in 52 payments from 17 companies in 2025. Trend: 2023 $1,104 · 2024 $632 · 2025 $1,010
Food & beverage: $1,010
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $228 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $158 |
| ABBVIE INC. | 4 | $87 |
| Lundbeck LLC | 4 | $81 |
| Vanda Pharmaceuticals Inc. | 3 | $81 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| Viatris Specialty LLC | 2 | $65 |
| Exact Sciences Corporation | 2 | $38 |
| Corcept Therapeutics | 2 | $35 |
| Amgen Inc. | 1 | $31 |
Products named: CAPLYTA, Wegovy, REXULTI, FANAPT, Auvelity, VRAYLAR, YUPELRI, Ozempic.
